Logo

Max Planck Institute Buys Cellomics ArrayScan Reader, Will Collaborate on High-Content Screening

Nov 02, 2005

NEW YORK, Nov. 2 (GenomeWeb News) - Cellomics will collaborate with Max Planck Institute in high-content screening development for drug discovery, Cellomics said last week.

 

As part of the agreement, the Max Planck Institute of Molecular Cell Biology and Genetics, located in Dresden, Germany, has purchased the Cellomics' ArrayScan VTI HCS Reader along with its complete portfolio of BioApplications and HCi informatics software.

 

The collaboration will include a mix of applications and new product development, as well as establishing a key demonstration center for Europe, said Daniel J. Calco, Cellomics' president, in a statement.

 

Cellomics, a unit of Fisher Biosciences, provides a cell-based platform.

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.